- Patent Title: Tricyclic compounds and their use as phosphodiesterase inhibitors
-
Application No.: US17886807Application Date: 2022-08-12
-
Publication No.: US12049465B2Publication Date: 2024-07-30
- Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Patrick Robert Verhoest , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Travis T. Wager , Ramalakshmi Yegna Chandrasekaran
- Applicant: PFIZER INC.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agency: Haley Guiliano LLP
- Agent James F. Haley, Jr.; Jacob E. Dander
- Main IPC: C07D471/14
- IPC: C07D471/14 ; C07D471/22 ; C07D487/04 ; C07D487/14 ; C07D491/147 ; C07D491/22 ; C07D498/22 ; C07D513/14 ; C07D519/00
Abstract:
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
Public/Granted literature
- US20230002386A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Public/Granted day:2023-01-05
Information query
